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This paper introduces Cancer Hybrid Automata (CHAs), a formalism to model the progression of
cancers through discrete phenotypes. The classification of cancer progression using discrete states
like stages and hallmarks has become common in the biology literature, but primarily as an organizing
principle, and not as an executable formalism. The precise computational model developed here aims
to exploit this untapped potential, namely, through automatic verification of progression models (e.g.,
consistency, causal connections, etc.), classification of unreachable or unstable states and computer-
generated (individualized or universal) therapy plans. The paper builds on a phenomenological
approach, and as such does not need to assume a model for the biochemistry of the underlying natural
progression. Rather, it abstractly models transition timings between states as well as the effects of
drugs and clinical tests, and thus allows formalization of temporal statements about the progression as
well as notions of timed therapies. The model proposed here is ultimately based on hybrid automata,
and we show how existing controller synthesis algorithms can be generalized to CHA models, so that
therapies can be generated automatically. Throughout this paper we use cancer hallmarks to represent
the discrete states through which cancer progresses, but other notions of discretely or continuously
varying state formalisms could also be used to derive similar therapies.
1 Introduction
Cancer is generally thought of as a progressive disease – in particular, a disease which exhibits certain
discernible cancer phenotypes (modeled as a finite set of discrete states), through which it progresses
towards a terminal phenotype (e.g., metastasis).
Among other theories, this view is reflected in the so-called hallmarks of cancer proposed by Hanahan
and Weinberg [8], and it has become one of the predominant ways of thinking about cancer, solidified
through many further publications and experiments. A recent article by the same authors [9] reviews and
consolidates the new insights of the last decade. Similar models have also been explored by a mechanistic
agent-based simulation in [1].
According to the model proposed by Hanahan and Weinberg, tumors must necessarily acquire certain
“intermediate” hallmarks culminating in the “final” hallmarks of tissue invasion and metastasis. As the
authors write,
Simply depicted, certain mutant genotypes confer selective advantage on subclones of cells,
enabling their outgrowth and eventual dominance in a local tissue environment. Accordingly,
multistep tumor progression can be portrayed as a succession of clonal expansions, each of
which is triggered by the chance acquisition of an enabling mutant genotype. [9, p. 658]
The current list of cancer hallmarks includes the abilities to reproduce autonomously, to ignore
anti-growth signals, or to signal for formation of new blood vessels, as well as handful of other phenotypes.
Hallmarks can be obtained in various different orders, but not every order is viable. Intuitively, a hallmark
can be acquired by a dominant sub-population of cells if it conveys a selective advantage compared to the
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other phenotypes acquired in that population. For example, in a wildly growing cluster of cells, the ability
to signal for new blood supply, and thus nutrients, oxygen, and waste disposal, will allow the respective
sub-population to outgrow the others.
Most hallmarks are acquired through mutations (point mutations, copy number changes or epigenetic
modifications) of very specific sets of oncogenes and tumor suppressor genes. Thus, many of the targeted
drugs, administered individually or combinatorially in a cocktail, which have been developed in recent
years, aim to influence the function of the products of these genes [16] and thus cancer’s evolution from
specific hallmarks. For example, the vascular endothelial growth factor (VEGF) signals for creation of
new blood vessels (angiogenesis), and the drug Avastin inhibits the associated signaling pathway, thus
preventing growing tumors from obtaining the needed blood supply. While current therapies target only
the observed hallmark at any instant, they rarely take into account the potential hallmarks that may evolve
in the future and the temporal structure of the underlying evolution. By connecting therapy design to
the theory of supervisory control of hybrid automata, we aim to build a framework for better therapy
design (e.g., that avoids drug-resistance, exploits synthetic lethality, oncogene addiction, etc., and avoids
undesirable side-effects on other organs).
In this view of cancer, its progression through hallmarks and therapy bears a striking resemblance to
formal models of state-transition machines in computer science.
In this paper, we first present a logical framework called Cancer Hybrid Automaton (CHA) that allows
us to formally capture cancer progression through accumulation of successive discrete states. States
in CHA models represent states of the progression, and directed edges among pairs of states define
possible progression paths. Drugs can then be thought of as inhibiting or prolonging specific transitions
in the automaton. We then show how this approach enables us to formally describe cancer progression,
automatically verify/model-check its temporal properties, and manipulate its evolution to satisfy certain
therapeutic goals.
We illustrate our approach through a highly simplified running example of a cancer hybrid automaton
in which states represent hallmarks, and progression paths represent successive hallmark acquisitions.
However, the states of the automaton can represent any set of discrete states at varying levels of abstraction.
Examples include stages of cancer, a set of affected pathways, and a set of specific genomic aberrations.
By ignoring complex structures such as heterogeneity, geometry, circulating tumor cells, tumor growth
dynamics, genomic instability at this point, we avoid obscuring the key ideas inherent to the therapy design
algorithms. However, the framework is flexible enough to include such structures as well as detailed
mechanistic models of the discrete states.
2 Overview
The rest of this paper is organized as follows. In section 3, we introduce a basic CHA formalism. In this
section, a CHA is modeled as a finite non-deterministic automaton. The edges, representing transitions
from one progression state (e.g hallmarks) to the next, are labeled with drugs that can inhibit the transition.
A therapy is defined as a function that assigns a set of drugs to each finite progression history, or run. An
execution of a therapy is defined as a run of the CHA that respects the therapy, that is, no transition of the
execution is inhibited by the therapy. Our model includes costs by associating a cost vector with each
state and each cocktail. Therapies may be selected by comparing costs of possible executions using a
notion of Pareto dominance, in addition to the required qualitative properties specified in CTL.
In section 4 we extend the CHA framework to include real time. In this model, transitions take certain
durations of time, and drugs can prolong (or stop) the transition process. This is modelled using a hybrid
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automaton with multiple clocks 1. Clock constraints on the edges and clock invariants at the states restrict
the possible progressions of the system. Multiple clocks are needed to allow for the scenario that a drug
affects the transition to possible next states in different ways. Possible runs and therapies of a timed CHA
now include the clock values. An extension of CTL, Timed CTL, is used to specify extended goals about
the system.
In section 5, we discuss the problem of automatically generating therapies, i.e., controller synthesis
for CHAs. For simple untimed CHAs this is a well-studied problem and algorithms exist. For timed
CHAs, we show that if we allow only for control at discrete moments in time the problem is decidable for
CTL goals.
Finally, section 6 concludes with a discussion of several possible extensions of our model, which will
be addressed in the future work.
3 Cancer Hybrid Automata
A simple, intuitive example CHA is shown in fig. 1. It comprises the following hallmarks (see [8] for
more details):
SSG: Self-sufficiency in growth signals. Roughly speaking, cells no longer depend on external growth-
promoting signals, but grow autonomously. Usually, such a state is associated with a gain of
function of an oncogene or a loss of function of a tumor suppressor gene.
IAG: Insensitivity to anti-growth signals. Cells with this hallmark continue to grow even in the presence
of inhibiting signals. Usually, certain cell-cycle checkpoints are no longer properly regulated.
Ang: Sustained angiogenesis. This state enables a cancer cell to signal for the construction of blood
vessels.
LRP: Limitless replicative potential. While most normal cells can only divide a certain number of
times, cells with this hallmark can divide without limits. In this state, a cancer cell may upregulate
telomerase to restore telomere lengths.
EvAp: Evading apoptosis. Normally, cells have a program for controlled cell-death, which is used to
remove damaged or otherwise unwanted cells. This program is disabled in this hallmark, which
allows cells with highly corrupted DNA to survive – thus facilitating cancer progression further.
M: Metastasis. This state enables cancer cells to spread from their original location to other parts of the
body.
Various possible progressions through these hallmarks can be seen as transitions in the picture (note
that this is a simplified and incomplete model). For example, Ang can be acquired after SSG and IAG.
Moreover, as mentioned in section 1, if a growing tumor fails to acquire Ang, it may starve; in this case, a
solid tumor is unable to grow further and attain the later hallmarks. For simplicity, it may be modeled as a
transition to the normal state.
In this example, the therapy “give the drug Avastin whenever a state leading up to Ang is reached”
will prevent the cancer from reaching M.
1Hence the term hybrid in ‘cancer hybrid automaton’.
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Figure 1: A simple CHA whose progression can be stalled by a VEGF-inhibitor such as Avastin.
3.1 Formal model
In the following, we start with a preliminary and simple formalization of the notions described above. We
will successively extend the formal model in the later sections.
We assume a global set D of drugs.
Definition 0.1. A Cancer Hybrid Automaton (CHA) is a tuple
H = (V,E,v0) ,
where
• V is a set of states,2
• E ⊆V ×2D ×V is a set of directed edges labeled with sets of drugs, and
• v0 ∈V is the initial state.
We usually omit v0 and write just (V,E).
Intuitively, an edge (v,D,v′) represents a transition from state v to state v′ that can be inhibited by any
drug from the set D⊆D . We allow several drugs to be given simultaneously and refer to such sets C ⊆D
of drugs as cocktails. Given a cocktail C, the edge (v,D,v′) ∈ E is inhibited by C if C∩D 6= /0. Given a
state v and a cocktail C, v can transition to v′ under C, in symbols v C−→ v′, if there is an edge (v,D,v′) that
is not inhibited by C. Note that we allow multiple edges (with different labels) between the same two
states. To prevent a transition between two states, all edges connecting them need to be inhibited, which is
why we need to consider cocktails rather than just single drugs. We assume that for every state v and every
cocktail C there exists some state v′ such that v C−→ v′ (possibly v′ = v, these edges were omitted in fig. 1).
A run of a CHA H = (V,E,v0) is a sequence of transitions in E. Let Runs(v,H) denote the set of
runs that start in v. We write Runs(H) for Runs(v0,H), and by Runsf(v,H) we denote the set of finite runs
from Runs(v,H).
We now formalize how it is possible to interfere with the progression of the system.
Definition 0.2. A therapy is a function pi : Runsf(H)→ 2D . A possible execution of pi in H is a run
S = v0v1v2 . . . ,
such that for each i≥ 0, vi pi(Si)−−−→ vi+1, where Si denotes the initial segment of S up to step i.
2Strictly speaking, in the case of hallmarks, a state corresponds to a subset of hallmarks that have been acquired.
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Definition 0.3. Costs are given by the following (overloaded) function, for some finite dimension n:
• c : V → Rn≥0 specifying costs of states,
• c : 2D → Rn≥0 specifying costs of cocktails.
Thus, both states and cocktails have costs assigned to them, represented as n-dimensional vectors.
Dimensions may include toxicity of the drugs, monetary cost of the drugs, discomfort for the patient, etc.
The cost of a possible execution S = v0v1v2 . . . of a therapy pi with discount factor 0< δ ≤ 1 is
c(S,pi,H) =∑
i≥0
δ i
(
c(vi)+ c(pi(Si))
)
.
The set of possible costs of pi for a CHA H is
c(pi,H) = {c(S,pi,H) | S is possible execution of pi in H}.
Now that we have a definition of the set of possible costs of a therapy, we can compare different
therapies with respect to their costs.
Definition 0.4. A cost vector x ∈ Rn Pareto-dominates another vector x′ ∈ Rn, in symbols x≺ x′, iff for
each 1≤ `≤ n we have x` ≤ x′` and for some 1≤ `≤ n we have x` < x′`.
A therapy pi Pareto-dominates a therapy pi ′ in a CHA H if for each x ∈ c(pi,H) and x′ ∈ c(pi ′,H) we
have x≺ x′. The set of candidate therapies for H is
Θ(H) = {pi |pi is not Pareto-dominated in H} .
For the special case of 1-dimensional costs (or if there is a function to aggregate cost vectors into
single numbers), the set of candidate therapies is the set of therapies whose best-case cost is not higher
than some other therapy’s worst-case cost.
This definition of a set of candidate therapies is a very conservative one, in that it includes any therapy
that is not overtly worse than some other therapy. There are different possibilities for defining the set of
candidate therapies, or for pruning the set further. Examples of such strategies for pruning the set further
include maximin, i.e., choosing those strategies that lead to the best worst-case outcome, or maximax,
i.e., choosing those strategies that lead to the best best-case outcome. However, making these decisions
depends on the risk attitude of patient and doctor which may not be fully formalizable. Therefore we
include all the potentially relevant therapies in the set of candidate therapies.
In order to be clinically applicable, a CHA model may need to be personalized for any given patient
or cancer type. This personalization will result in families of CHAs, with different sets of candidate
therapies. While we will not give full details here, we wish to describe one possible application for such
richer models.
For families of automata, we can ask whether there are any universal therapies for all of the included
automata. Such therapies can result in faster and cheaper treatments.
To be able to apply therapies across different automata, their domain must be the same. This
requirement can be satisfied, for example, by considering CHAs that contain the same set of hallmarks,
and therapies that either depend only on the current state, or that have the set of all sequences of states as
domain. The following definition applies to therapies on such unified domains.
Definition 0.5. Given a family H of CHAs, the set of (universal) candidate therapies for H is
Θ(H ) =
⋂
H∈H
Θ(H) .
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A set θ of therapies coversH if
θ ∩Θ(H) 6= /0 for all H ∈H .
Note that if Θ(H ) 6= /0 then for each pi ∈Θ(H ), {pi} covers H .
3.2 Temporally extended goals: CTL
We have seen in the previous section that therapies can be compared according to their costs. Thus, the
problem of finding the right therapy can be viewed as an optimization problem. It can, however, be
necessary to have more detailed control over the therapeutic objectives. Simple reachability properties
can be used as goals, such as “metastasis must never be reached”. For more expressivity we can use
Computation Tree Logic (CTL) [4] to specify goals.
Example 1. The goal AG¬M states that metastasis is never reached. Another possible goal could be
AG(Ang→ AG¬EvAp) .
This sentence means that whenever sustained angiogenesis is acquired, then at no point in the future the
capability of evading apoptosis will be obtained.
One may be interested in checking properties of the CHA itself, without application of a therapy. This
goal can be achieved by using CTL model checking (see, e.g., [5]). CTL properties can also be checked
on the possible executions of a given pair of therapy and untimed CHA. Supervisory control for finite
automata with CTL goals is known to be EXPTIME-complete, and controller synthesis algorithms exist
[15].
The above representation of a cancer automaton is intuitive, but it does not include timing. It fails
to model the fact that some transitions could be very short while others may take many years. In the
next section we introduce timed CHAs, which are automata equipped with a set of real-valued variables,
denoted as clocks, and constraints on the edges and states restrict the progression of the system. This
model will be a special kind of hybrid automaton, justifying the word hybrid in ‘cancer hybrid automata’.
4 Timed CHAs
The framework we built so far is somewhat idealized in that transitions occur spontaneously and drugs
can switch off transitions completely. More realistically, transitions would take certain durations of time,
and drugs can slow down (or stop) the transition process. For example, in pancreatic cancer, it takes about
a year for K-ras mutations in a cell to lead to neoplasms (so-called PanINs) [14]. To model durations, we
will now add a notion of time to our CHA framework.
We start with the assumption that the acquisition of a hallmark requires a certain minimum amount
of time. We do not specify exactly how that time is determined, but it could be the stopping time of
a stochastic process such as randomizing over a set of driver mutations, or some value obtained from
clinical data. Only after that time a given transition will be possible, and as mentioned, drugs can be used
to prolong this time.
Further, we allow states to have invariants, specifying the maximum time that the system can remain
in the respective state. For example, a tumor may only be able to remain in a state of unbounded growth
without angiogenesis for a certain number of months.
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Figure 2: A simple timed CHA. The edges are labeled with the minimum times needed to make the
respective transitions. In the two states that lead up to Angiogenesis, Avastin can be given to slow down
the progress by half. Those states are labeled with invariants, and depending on the precise timing, these
invariants can force the system back to Normal before the transition to Angiogenesis is possible.
Figure 2 shows the automaton from fig. 1 with timing information added, illustrating this intuition.
We formalize the extension in the following.
We assume a finite set X of real-valued variables called clocks, over which the set of constraints C (X)
is generated according to the grammar
φ ::= x≥ k | φ ∧φ ,
where k ∈N and x ∈ X . A valuation of the variables in X is a mapping val : X →R≥0. We denote the null
valuation x 7→ 0 by 0. By val |= φ we denote that val satisfies φ .
Definition 1.1. A timed CHA is a tuple H = (V,E,v0, `,ρ) where
• V is a set of states,
• E ⊆V ×C (X)×V is a set of directed edges each labeled with a clock constraint,
• v0 ∈V is the initial state,
• ` : V ×X → N is a partial function specifying the time limit (if any) for each clock that the system
can remain in a given state (this is also called the invariant), and
• ρ : V ×D×X →R≥0 yields a function specifying how a given drug influences the clocks at a given
state.
Intuitively, at a given state v, the drug d modifies the clock rate, by slowing down or speeding up the
clock x as specified by a multiplicative factor ρ(v,d,x). When the factor is 1, the drug has no effect on
that clock, and when it is 0, it effectively stops the clock from progressing. If several drugs have an effect
on a clock, their factors are multiplied. We extend ρ to cocktails by setting ρ(v,C,x) =∏d∈C ρ(v,d,x)
for any cocktail C 6= /0, and by convention, ρ(w, /0,x) = 1.
A directed edge (v,φ ,v′) represents a transition from v to v′ that can take place once the time constraint
φ is satisfied.
We assume that for each state v that has a time limit for a clock x, there is an outgoing edge (v,φ ,v′)
such that val |= φ for all val with val(x) = `(v,x).3 This edge specifies the behavior of the system if the
respective clock reaches its time limit.
3Note that this requires val |= φ even for valuations that exceed some other clock’s invariant; however, this does not have an
effect since we only allow ≥ constraints on the edges.
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The cost functions in the context of timed CHAs are the same as those for the untimed version, but
with a timed interpretation: c(v) is the cost of staying at state v per time unit (days/weeks/months/years),
and c(C) is the cost of administering a drug cocktail C per time unit.
We next see how to adapt the definitions related to runs of a CHA to the timed version, starting with
the notion of a timed state.
Definition 1.2. A timed state of a timed CHA (V,E) is a tuple (v,val) ∈V ×RX , where v is a state and
val a clock valuation. There are two types of transitions between timed states:
1. Delay transitions, in symbols (v,val)
δ ,C−−→ (v,val′), where
• δ ∈ R>0 represents the (real) time delay,
• C denotes the cocktail active during that time,
• val′(x) = val(x)+δρ(v,C,x) for all x, and
• val′(x)≤ `(v,x) for all x with `(v,x) defined.
2. State transitions, in symbols (v,val)→ (v′,0), where
• there is an edge (v,φ ,v′) ∈ E with val |= φ .
Note that whenever a state transition takes place, the clocks are reset. This strategy simplifies our
presentation and could be replaced by explicit clock resets as common in the literature.
This setup includes the special case where there is one clock unaffected by any drug, representing real
time. Invariants over that clock can be used to specify, for example, the duration over which the tumor can
remain in a certain state.
This timed setup can also emulate the concept of edges labeled with drugs that inhibit them. This
model can be constructed as follows: Suppose we want to model an edge between two states v,v′ that can
be inhibited by a drug d. Then we can introduce a clock variable xd,v′ with ρ(v,d,xd,v′) = 0, and add a
constraint xd,v′ ≥ z to the edge between v and v′, for some z > 0. As long as drug d is given before the
constraint is satisfied, the transition will be inhibited. However, once the constraint is satisfied, the tumor
has advanced too far and it is no longer possible to inhibit the transition.
A run in the case of a timed CHA H is a non-Zeno4 sequence of delay and state transitions. Similar
as before, let Runs((v,val),H) denote the set of runs that start in (v,val). We write Runs(H) for the set
Runs((v0,0),H), and Runsf((v,val),H) for the set of finite runs from Runs((v,val),H).
Definition 1.3. A therapy is a function pi : Runsf(H)→ 2D . A possible execution of pi in H is a run
S = (v0,0)(v1,val1)(v2,val2) · · ·
such that for all i with delay transitions (vi,vali)
δ ,C−−→ (vi+1,vali+1),5 for every 0≤ δ ′ < δ
pi((v0,0) . . .(vi,vali)(vi,vali +δ ′ρ(vi,C))) =C,
where ρ(vi,C) denotes the partial evaluation of ρ , i.e., the function x 7→ ρ(vi,C,x).
This last condition ensures that the therapy does not change during a transition, or, put differently, that
a change in therapy is always reflected by starting a new transition.
4That is, not containing an infinite chain of timed transitions with convergent total duration.
5Note that vi = vi+1.
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For any finite run r ∈ Runsf(H), we denote its duration as
τ(r) = ∑
0≤ j<len(r)
{
δ if r j
δ ,C−−→ r j+1 for some δ ,C
0 otherwise,
where len(r) denotes the length of the state sequence in r and ri its initial segment of length i.
Definition 1.4. Given a CHA H and a possible execution S of a therapy pi , the cost of S given pi with
discount factor 0< d ≤ 1 is
c(S,pi,H) =∑
i≥0
1
d
(
e−dτ(Si)− e−dτ(Si+1)
)
(c(vi)+ c(pi(Si)))
(as before, by Si we denote the initial segment of S up to step i). This simple discounting function does not
necessarily capture a real patient’s preferences, but any convergent function will work in its stead. We
will consider more realistic functions in the future, which can potentially be designed on a case-by-case
basis depending on the patient’s valuation.
The set of possible costs of pi in a timed CHA H is the set of costs of possible executions of pi ,
c(pi,H) = {c(S,pi,H) | S is possible execution of pi in H}.
The notions of Pareto dominance and universal therapies carry over from untimed CHAs.
4.1 Timed CTL
We can extend the CTL goals of the previous section to include time [2]. For example, the goal AG≤20¬M
says that metastasis is not reached within 20 time units (e.g., 20 years). This kind of goal represents the
approach of turning cancer into a chronic disease, rather than trying to cure it completely. For example,
the above formula may be appropriate for a patient of sixty years of age, who may then be able to get a
less strenuous therapy, while for a younger patient the time requirements may be more extensive.
Out of all the therapies satisfying a CTL goal, the best ones may be chosen either by a separate cost
optimization, or by incorporating cost requirements into the formulas using a weighted version of CTL [3].
5 Automatic therapy design for CHAs
Given the complexity of (timed) cancer progression and the influence of various drugs, the task of finding
near-optimal therapy plans is (soon to be) beyond manual planning, and automated computational tools
are very desirable.
The controller synthesis problem for different classes of automata have been studied in the literature,
often restricted to achieving safety (avoiding a set of ‘bad’ states) and reachability (eventually reaching
a ‘goal’ state) properties. Such properties form a sub-class of what can be expressed in richer temporal
logics such as CTL. Safety properties are especially relevant for CHAs, because goals such as “metastasis
will never be reached” can be expressed.
Untimed CHAs are a special kind of discrete automata for which efficient controller synthesis
algorithms exist and can be applied to automatically design therapy-plans (see e.g. [18] for control using
safety goals and [15] for an algorithm that uses CTL specifications).
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Control of timed CHAs For timed CHAs, however, control is not as straightforward. CHAs are a
special class of hybrid automata. Unfortunately, in hybrid systems, even simple verification and control
problems like reachability and safety are undecidable [12]. However, several decidable subclasses of
hybrid automata exist for which algorithms have been devised. One such subclass is that of rectangular
hybrid automata. A rectangular automaton is an automaton in which the clock constraint on each edge is a
rectangular region of continuous states. That is, it specifies for each clock a (possibly unbounded) interval
that should contain its value. Also, the clock speed at each state is assumed to be bounded from below
and above.
Rectangular automata form a most general class of hybrid automata for which even the reachability
model checking problem is decidable [12, 10] and controller synthesis algorithms have been developed.
For example, in [10] Henzinger et al. show that the control problem with LTL specifications is EXPTIME-
complete in the size of the game, and 2EXPTIME-complete in the size of the formula.
These results rely on the requirement that the rectangular hybrid automata satisfies a property called
initialization or constant reset. Initialization states that whenever the speed of a clock changes after a
transition, the value of the variable is reinitialized to a fixed value (or a value in a fixed interval). This
property cannot be relaxed without making the control problem undecidable [12]:
From timed CHAs to rectangular hybrid automata Timed CHAs bear a striking resemblance to
rectangular hybrid automata, and it is thus worth exploring whether some of the controller synthesis
results and algorithms can be applied to CHA models as well. Unfortunately, existing decidability results
do not carry over directly because of some important differences between CHAs and (rectangular) hybrid
automata.
First, in the hybrid automata literature, the rates of the clocks are generally assumed to be constant
at any given state6 and what is controllable are (some of) the transitions between states. In the CHA
framework, in contrast, the rates of the clocks is what can be affected by control actions (drugs), while
the transitions (tumor progression) cannot be directly manipulated. However, this difference is mainly
conceptual as a timed CHA can be translated to a hybrid automaton as follows:
Given a set of drugs D and a CHA H with states V , we construct a hybrid automaton RH in the
following way: For each state v ∈V and each cocktail C ∈ 2D , RH contains a state vC with the same clock
invariants as v. For any edge between two states v,v′ ∈V , RH contains an uncontrollable edge between vC
and v′C, for each cocktail C, with the same clock constraints and resets as on the CHA edge. In addition to
the uncontrollable edges, there are controllable directed edges from vC to vC′ for each v, C and C′. These
edges represent changes of therapies, and have no clock constraints or resets. At a state vC, the rate of
each clock x ∈ X is fixed, given by ρ(v,C,x). This translation yields an automaton of size exponential in
the number of drugs, but linear in the number of CHA states.
The result is a rectangular hybrid automaton. However, the translated CHA does not satisfy initializa-
tion, as the clock values (indicating progression time) are kept along controllable (change of cocktail)
transitions while changing the rates of the clock. Thus, the negative results of Henzinger et al. [10] are no
longer applicable.
Discretized control The simplest way around the undecidability of the control problem for rectangular
hybrid automata that do not satisfy initialization is to allow for control moves (in our case, therapeutic
interventions) only at discrete instants of time. Henzinger and Kopke [11] give an exponential-time
algorithm for discrete-time safety control with CTL goals of rectangular hybrid automata with bounded
6One exception are so-called differential games [17], but their theory has not been well developed.
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and non-decreasing variables. They also show the problem to be EXPTIME-hard and discrete-time
verification of rectangular hybrid automata to be solvable in PSPACE.
Even though our definition of timed CHAs does not require clocks to be bounded, such a restriction
would not impose a severe limitation. By bounding the clocks by some value that even the healthiest
patient will never reach, we can thus aim for decidability without forfeiting any meaningful therapy. The
algorithms from [11] do not directly apply to CHAs as their framework requires all discrete transitions
to be controllable, whereas our cancer progression transitions are uncontrollable. However, they can be
extended to include our framework via the following theorem, for which we only provide a sketch of the
proof. The full proof can be found in the extended version of this paper.
Theorem 2 (Discrete control of bounded CHAs). The controller synthesis problem of bounded discretized
CHAs for CTL formulae can be solved in EXPTIME.
Proof Sketch: First, we can translate the bounded CHA H into a rectangular hybrid automaton RH as
described earlier. Then, the rectangular hybrid automaton RH can be described as a hybrid game 7 HG by
specifying that the controller is only allowed to make moves that include a change of therapy: from c to c′
at state v by moving from (v,c) to (v,c′), and cancer is only allowed to pick an accessible new CHA state
from the available ((v,c)(v′,c)) transitions.
Next we can extend the discretization method as given in [11] for rectangular automata to hybrid
games. We can define a sampling control game DHG in which the players can only make one move every
time unit, by adding a new variable xn+1 such that `(v,xn+1) = 1 at each state; each clock constraint φ in
the automaton becomes φ ∧ xn+1 ≥ 1 (0≤ xn+1 ≤ 1); the rate of xn+1 is 1 at all states; and xn+1 is reset to
0 after each discrete transition. This construction guarantees that moves by the cancer and therapist are
always followed by a delay transition of duration 1 8.
We can then define a bisimulation relation on the states of the discretized hybrid game DHG as in
[11] as follows: We define an equivalence relation ≈n on Rn (the set of clock valuations) such that y≈ z
iff byic = bzic and dyie = dzie for all a ≤ i ≤ n. Now, given two states (v,val) and (v′,val′) we define
(v,val)∼=DHG (v′,val′) if v = v′ and val≈ val′. (we can also define (v,val)∼=mDHG (v′,val′) for a bound m ).
We can show that this is indeed a bisimulation preserving CTL satisfaction, and since the result is a finite
representation (exponential in size) of the original CHA, it follows that control of discretized bounded
CHAs with CTL goals is solvable in EXPTIME. 
6 Conclusions
This paper establishes a general formalism for describing cancer progression, without relying on any
detailed mechanistic model of cancer pathways (which can be included independently as models of the
discrete states). Our goal was to design a conceptually clear framework based on realistic biological
foundations. As a case study, we have used this model to describe cancer hallmarks and their dynamics.
We discuss below how our framework can be used, as is, to model phenomena beyond what we
discussed so far. Then, we point out the limitations of the current paper and give a list of topics that we
plan to address in the near future.
7A game automaton is an automaton in which two players can make discrete moves. In our case not only the controller but
also nature/the cancer can make discrete moves.
8Note, you have to assume that the automton is big enough: in the original automaton it is not possible to make two moves in
one time unit.
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Figure 3: Illustrating how to model an anti-hallmark using two clocks x and y and a drug d that speeds up
clock y at Hallmark 1 by a factor of 2.
6.1 Modeling growth, heterogeneity and anti-hallmarks
More general clocks: Thus far, we have referred to the clocks in CHAs as measuring time. However,
they could be measuring different properties like tumor size, motility or spatial properties. For example,
in the case of tumor size, the growth rate of the tumor may depend on the current discrete states of
the progression and drugs can influence this rate. With this model we can reproduce the tumor growth
dynamics as described in [22], by introducing two clocks: one measuring the number of stem cells and
the other the number of differentiated cells. The various mutations can be modeled as transitions to a next
state with different growth dynamics depending on the mutations already acquired.
Heterogeneity in tumors: So far we have modeled states of a CHA as representing the unique dominant
phenotype of the tumor cell population. However, most forms of cancer are not likely to be monoclonal,
i.e., consist of only one population in which the clonal expansions postulated by Hanahan and Weinberg
take place, but rather involve several sub-populations of tumor cells [19], each with a distinct dominant
phenotype [7, 13]. In order to model this heterogeneity, we can simply think of a CHA state as representing
a vector of dominant phenotypes, one for each sub-population. One or several components of such a
vector may differ from one state to the next, corresponding to a change of the dominant phenotype in
the corresponding sub-population(s) during the respective transition; or the length of the vector may
change, corresponding to new distinct sub-populations emerging or existing sub-populations dying out.
This approach is, however, rather crude in modeling tumor heterogeneity, and does not straightforwardly
accommodate, for example, information about tumor geometry or a model of the resulting spatial effects.
Anti-hallmarks Instead of trying to slow down cancer progression, there has recently been growing
interest in approaches to speed up the process to a degree which will make the tumor nonviable and “push
it over the edge” towards collapse. We refer to such nonviable states as anti-hallmarks. They can be
modeled by putting constraints on the transitions leading to them that will never be satisfied, unless a drug
is given which speeds up a certain clock. For example, consider the CHA in fig. 3. At Hallmark 1, without
interference (both clocks increase with rate 1), the transition to Hallmark 2 will be taken after 4 time units.
A drug that speeds up clock y by a factor of 2 will instead push the tumor to the Anti-Hallmark state, if
given starting at most 1 time unit after entering Hallmark 1.
6.2 Extensions and Future Work
Partial observability and tests: The framework introduced in this paper assumes perfect information
about the state of the system. In reality however, a clinician will only have partial observations of the
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tumor’s internal state. To reduce uncertainty about the current state of the cancer progression, tests can
be performed. Our formal framework can be extended to include partial observability and tests, both
for untimed and timed CHAs. Partial knowledge about the tumor’s internal state can be modeled by
introducing the notion of a belief set. Tests can be incorporated into the definition of a therapy as actions
that reduce uncertainty about the current state. A therapy can then be described as a function from the set
of belief-runs to cocktails or tests. The details appear in the full paper.
Compositional models: In a patient, cancer itself is not the only system of relevance. Other systems
interact with the tumor’s development, and especially during a therapeutic intervention, they need to be
monitored. For example, the immune system and its role throughout carcinogenesis are receiving more
and more attention [23], and the liver needs to be monitored to avoid damage due to excess toxicity. In
principle, other subsystems of an organism could be modeled as hybrid automata in the same way as our
CHA, which could then be composed to an overall model for which therapies with goals spanning all
subsystems could be generated.
Building on our conceptual foundation, we plan to address several important issues next.
Algorithmic issues: In section 5, we have shown that the controller synthesis problem for timed CHAs
is decidable if both the therapist and the cancer are only allowed to make moves at discrete moments in
time. In the future, we plan to focus more on to the algorithmic side of verifying cancer hallmark automata,
automatically generating therapies (including cost minimization), finding promising drug targets, etc.
Model extraction: Finally, we omitted a description of the methodologies needed for extracting cancer
phenotypes and their temporal progression models from data or mechanistic pathway and population
models. For example, there is currently no consensus that the cancer hallmarks described in the literature
constitute a complete list, nor is there a clear understanding (either phenomenologically or mechanistically)
of their precise discrete dynamics. We also believe that spatial structure (geometry, growth curve, spatial
distribution of heterogeneity, etc.) as well as motility (self-seeding, circulating tumor cells) may hold
additional and important clues that can be easily incorporated into our therapy design [6, 20]. Therefore,
we plan to extract models from spatio-temporal data, for example, data obtained from detailed simulations,
or gene expression and imaging data from patients or mouse models. We plan to use statistical inference
algorithms for model extraction (such as GOALIE [21]) in order to reconstruct temporal (or spatio-
temporal) phenomenological models of cancer-related processes from such data.
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